Doron Harlev

Doron Harlev is the founder and CEO of Affera, Inc., a medical technology company focused on developing innovative solutions for treating cardiac arrhythmias.12 His career has been marked by significant achievements in the field of medical technology, particularly in cardiac mapping and ablation systems.

Professional Background

Entrepreneurial Ventures:

Harlev co-founded Rhythmia Medical, where he served as co-CEO.1 Rhythmia developed a unique Electroanatomical Mapping System for treating cardiac arrhythmias. In 2012, Boston Scientific acquired Rhythmia, and it became their cardiac mapping and navigation division.12

Corporate Experience:

After the acquisition, Harlev took on the role of Vice President of Product and Technology at Boston Scientific.12 This position allowed him to continue his work in advancing cardiac mapping and navigation technologies.

Current Role:

As the founder and CEO of Affera, Harlev leads a company dedicated to developing a comprehensive integrated platform for efficiently delivering durable therapy to cardiac arrhythmia patients.23 In August 2022, Medtronic completed the acquisition of Affera, further expanding its cardiac ablation portfolio.3

Education and Expertise

Harlev's educational background includes:

• MBA from MIT Sloan
• M.Sc. in Electrical Engineering from Tel Aviv University
• B.Sc. in Electrical Engineering from the Technion Israel Institute of Technology12

Innovations and Contributions

Harlev is a prolific inventor, holding over 160 issued and pending patents.2 His work at Affera has led to the development of several innovative technologies, including:

• The Affera Prism-1™ cardiac mapping and navigation platform
• The Sphere-9™ cardiac diagnostic and ablation catheter
• Other pipeline products like the Arc-10 coronary sinus diagnostic catheter and Sphere PVI ablation catheter3

Industry Impact

Under Harlev's leadership, Affera has made significant strides in addressing the growing demands for cardiac arrhythmia treatment. The acquisition by Medtronic is expected to enhance and accelerate Affera's ability to treat millions of patients worldwide suffering from cardiac arrhythmias.3

Harlev's vision for Affera involved creating technology with physicians and patients in mind, aiming to advance the field of electrophysiology while supporting safe and efficient cardiac ablation procedures.34